9DC Stock Overview
Daicel Corporation engages in the materials, medical/healthcare, smart, safety, engineering plastics, and other businesses in Japan, China, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 4/6 |
Daicel Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥8.60 |
| 52 Week High | JP¥9.35 |
| 52 Week Low | JP¥7.05 |
| Beta | 0.62 |
| 1 Month Change | -5.49% |
| 3 Month Change | -2.27% |
| 1 Year Change | 21.99% |
| 3 Year Change | 39.84% |
| 5 Year Change | -12.55% |
| Change since IPO | -25.22% |
Recent News & Updates
Recent updates
Shareholder Returns
| 9DC | DE Chemicals | DE Market | |
|---|---|---|---|
| 7D | 1.2% | -1.6% | 0.5% |
| 1Y | 22.0% | 0.9% | 1.3% |
Return vs Industry: 9DC exceeded the German Chemicals industry which returned -0.3% over the past year.
Return vs Market: 9DC exceeded the German Market which returned 2.3% over the past year.
Price Volatility
| 9DC volatility | |
|---|---|
| 9DC Average Weekly Movement | 4.5% |
| Chemicals Industry Average Movement | 4.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 9DC has not had significant price volatility in the past 3 months.
Volatility Over Time: 9DC's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1919 | 11,207 | Yoshimi Ogawa | www.daicel.com |
Daicel Corporation engages in the materials, medical/healthcare, smart, safety, engineering plastics, and other businesses in Japan, China, and internationally. The company offers acetic acid, acetic acid derivative chemicals, acetate tow, acetic anhydride, thioglycolic acid, caprolactone derivatives, methyl 3-methoxyacrylate, cycloaliphatic epoxies, alkylamines comprising diethylhydroxyamine, and 1,3-butylene glycol, as well as cellulose acetate; and Actranza Lab, a drug delivery device. It also provides solutions for the electronics market, such as functional films and materials for use in smartphones, PCs, TVs, and in-vehicle displays; polymers and solvents for use in the semiconductor manufacturing process; optical lenses for use in VR, smartphones, and various sensors; printed electronic materials; and organic semiconductors.
Daicel Corporation Fundamentals Summary
| 9DC fundamental statistics | |
|---|---|
| Market cap | €2.35b |
| Earnings (TTM) | €331.49m |
| Revenue (TTM) | €3.28b |
7.1x
P/E Ratio0.7x
P/S RatioIs 9DC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9DC income statement (TTM) | |
|---|---|
| Revenue | JP¥547.79b |
| Cost of Revenue | JP¥396.75b |
| Gross Profit | JP¥151.04b |
| Other Expenses | JP¥95.69b |
| Earnings | JP¥55.34b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 09, 2024
| Earnings per share (EPS) | 200.65 |
| Gross Margin | 27.57% |
| Net Profit Margin | 10.10% |
| Debt/Equity Ratio | 92.9% |
How did 9DC perform over the long term?
See historical performance and comparison